The Stem Cell Therapeutic and Research Reauthorization Act of 2026 (S. 4109) is a bipartisan bill introduced in the U.S. Senate to continue and enhance federal support for programs that connect patients with life-threatening blood cancers and other diseases to stem cell donors and cord blood units. Specifically, the bill reauthorizes the C.W. Bill Young Cell Transplantation Program and the National Cord Blood Inventory for an additional five years, ensuring the ongoing facilitation of bone marrow and cord blood transplants. The legislation proposes funding of $31,009,000 for the current fiscal year, with an increase to $33,009,000 for each fiscal year from 2027 through 2031. This funding aims to support the collection and management of cord blood units and to improve patient outcomes through continued access to life-saving transplants.
The introduction of S. 4109 has been met with strong support from various organizations and stakeholders. The National Marrow Donor Program (NMDP) praised the bipartisan effort, highlighting that the program has facilitated nearly 150,000 transplants since its inception, with a 33% increase in the last five years. NMDP emphasized that reauthorizing the program could impact over 40,000 lives in the next five years. Additionally, AABB, an association representing transfusion medicine and cellular therapies, expressed support for the legislation, noting its importance in connecting patients with life-saving treatments. The bill's bipartisan sponsorship by Senators Jack Reed (D-RI), Tim Scott (R-SC), Tina Smith (D-MN), and James Lankford (R-OK) has been highlighted as a positive indicator of its potential for passage.
As of now, there is limited negative media coverage or criticism regarding S. 4109. However, potential concerns could arise regarding the allocation of federal funds and the effectiveness of the programs in achieving desired outcomes. Some stakeholders might question whether the proposed funding levels are sufficient to meet the growing demand for stem cell transplants or whether the programs are operating efficiently. Additionally, ethical debates surrounding stem cell research and therapy could lead to opposition from certain groups, although this bill focuses on adult stem cells and cord blood, which are generally less controversial than embryonic stem cell research.
The analysis of the Stem Cell Therapeutic and Research Reauthorization Act of 2026 reveals no direct industry overlaps between the sponsor, John Reed, and his top donor industries. The primary lobbying activity in this policy area comes from various entities, including Fresenius Kabi USA LLC, which has contributed $1,100,000. However, this company is not directly related to stem cell research but is involved in pharmaceuticals and medical technologies. The absence of direct connections between the bill's subject matter and the sponsor's donors suggests a lower risk of conflicts of interest. Voters should be aware that while lobbying exists, the lack of direct financial ties mitigates potential concerns.
Organizations that lobbied on issues related to this bill's policy area.
| Client | Lobbying Firm | Amount |
|---|---|---|
| FRESENIUS KABI USA LLC | FRESENIUS KABI USA LLC | $1,100,000 |
| CONSEJO COORDINADOR EMPRESARIAL | IQOM STRATEGIC ADVISORS, LLC | $140,000 |
| IVANHOE ATLANTIC (FORMERLY HIGH POWER EXPLORATION INC.) | YORKTOWN SOLUTIONS | $120,000 |
| SKYRYSE, INC. | SKYRYSE, INC. | $70,000 |
| AIS HEALTHCARE | MCGUIREWOODS CONSULTING (A SUBSIDIARY OF MCGUIREWOODS LLP) | $20,000 |
| THE FERGUSON GROUP, LLC ON BEHALF OF WEST COUNTY WASTEWATER DISTRICT, CA | EARL STOCKDALE | undisclosed |
| THE FERGUSON GROUP, LLC FOR CITY OF OCEANSIDE CA | EARL STOCKDALE | undisclosed |
| THE FERGUSON GROUP, LLC ON BEHALF OF WARD & SMITH (FOR BALD HEAD ISLAND) | EARL STOCKDALE | undisclosed |
| THE FERGUSON GROUP, LLC ON BEHALF OF WARD & SMITH, PA (FOR HOLDEN BEACH, NC) | EARL STOCKDALE | undisclosed |
| CORE POWER (US) INC. | INVARIANT LLC | undisclosed |
| ICON TECHNOLOGY, INC. | INVARIANT LLC | undisclosed |
| HUBBS-SEAWORLD RESEARCH INSTITUTE | HAMMER ASSOCIATES, LLC | undisclosed |
| THE POLICY SHOP LLC | JAVELIN ADVISORS LLC | undisclosed |
| NATIONAL ALLIANCE OF HEALTHCARE PURCHASER COALITIONS | NATIONAL ALLIANCE OF HEALTHCARE PURCHASER COALITIONS | undisclosed |
| EARTHSHIP CORPORATION | RED DOOR CONSULTING, LLC | undisclosed |
Source: Senate Lobbying Disclosure Act (LDA) filings, 2026
